MD480Z - Method for treating acute ulcerative nonspecific colitis - Google Patents
Method for treating acute ulcerative nonspecific colitis Download PDFInfo
- Publication number
- MD480Z MD480Z MDS20110128A MDS20110128A MD480Z MD 480 Z MD480 Z MD 480Z MD S20110128 A MDS20110128 A MD S20110128A MD S20110128 A MDS20110128 A MD S20110128A MD 480 Z MD480 Z MD 480Z
- Authority
- MD
- Moldova
- Prior art keywords
- day
- administered
- aminosalicylic acid
- solution
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 230000001154 acute effect Effects 0.000 title claims abstract description 4
- 208000025865 Ulcer Diseases 0.000 title abstract description 4
- 206010009887 colitis Diseases 0.000 title abstract 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960004963 mesalazine Drugs 0.000 claims abstract description 27
- 210000001072 colon Anatomy 0.000 claims abstract description 10
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 10
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 7
- 239000006260 foam Substances 0.000 claims abstract description 7
- 102000009027 Albumins Human genes 0.000 claims abstract description 6
- 108010088751 Albumins Proteins 0.000 claims abstract description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 6
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 238000001784 detoxification Methods 0.000 claims abstract description 4
- -1 1-ethylpyrrolidin-2-yl Chemical group 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 19
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 19
- 239000007920 enema Substances 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 6
- 229940095399 enema Drugs 0.000 claims description 5
- 229940079360 enema for constipation Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000008279 sol Substances 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 4
- 241000792859 Enema Species 0.000 description 3
- 229940072224 asacol Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000741 diarrhetic effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000035611 feeding Effects 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000005353 urine analysis Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 206010028124 Mucosal ulceration Diseases 0.000 description 1
- 101100010166 Mus musculus Dok3 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- YFUATOCFMCWUEH-UHFFFAOYSA-N chembl2105427 Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N=NC=2C=C(C(O)=CC=2)C(O)=O)C=C1 YFUATOCFMCWUEH-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 206010036784 proctocolitis Diseases 0.000 description 1
- 208000017048 proctosigmoiditis Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000012794 white bread Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Invenţia se referă la medicină, în special la proctologie şi poate fi utilizată în tratamentul colitei ulceroase nespecifice acute. The invention relates to medicine, in particular to proctology and can be used in the treatment of acute nonspecific ulcerative colitis.
Rectocolita ulceroasă nespecifică prezintă o problemă a coloproctologiei, deoarece etiologia bolii rămâne necunoscută, iar tratamentul specific la moment lipseşte, are debut recidivant şi pronostic medicosocial nefavorabil. Recidivele frecvente ale bolii, riscul înalt de malignizare, complicaţiile grave locale (intestinale) şi generale (caşexie) necesită căutarea metodelor noi de tratament. Nonspecific ulcerative colitis presents a problem in coloproctology, because the etiology of the disease remains unknown, and specific treatment is currently lacking, it has a recurrent onset and an unfavorable medico-social prognosis. Frequent relapses of the disease, the high risk of malignancy, serious local (intestinal) and general complications (cachexia) require the search for new treatment methods.
În prezent este cunoscut tratamentul complex al rectocolitei ulceroase nespecifice, care include alimentarea dietetică, corijarea metabolismului proteic, hidroelectrolitic prin hemotrasfuzii de masă eritrocitară, plasmă, albumină, soluţii glucozo-saline, preparate antiinflamatoare. Currently, the complex treatment of nonspecific ulcerative colitis is known, which includes dietary nutrition, correction of protein and hydroelectrolytic metabolism through blood transfusions of red blood cells, plasma, albumin, glucose-saline solutions, and anti-inflammatory drugs.
În tratamentul rectocolitei ulceroase nespecifice o importanţă deosebită prezintă dietoterapia. Se recomandă dieta nr. 4 sau 4b, care conţine carne degresată fiartă, ouă, pâine albă, orez fiert 40 minute, jeleu de fructe 1,5 litri pe zi, miez de nucă, iar la acutizarea bolii - măcieş, sucuri de portocale şi tomate. In the treatment of nonspecific ulcerative colitis, diet therapy is of particular importance. Diet No. 4 or 4b is recommended, which contains boiled lean meat, eggs, white bread, rice boiled for 40 minutes, fruit jelly 1.5 liters per day, walnut kernels, and in case of exacerbation of the disease - rose hips, orange and tomato juices.
Principiile alimentării raţionale trebuie să excludă alimentele prăjite, grase, produsele lactate, cu excepţia brânzei de vacă degresate, bucatele copioase şi sărate, ciocolata, boboasele, ciupercile, legumele şi fructele proaspete. În remisiune îndelungată asortimentul de alimente se măreşte, însă produsele lactate se limitează sau se anulează. The principles of rational nutrition should exclude fried, fatty foods, dairy products, except for low-fat cottage cheese, hearty and salty dishes, chocolate, berries, mushrooms, fresh vegetables and fruits. In long-term remission, the range of foods increases, but dairy products are limited or eliminated.
La acutizarea maladiei alimentarea trebuie să fie în porţiuni mici, dar mai frecventă. În caz de diaree intervalele dintre alimentări nu trebuie să depăşească 2,5 ore. During an exacerbation of the disease, feeding should be in small portions, but more frequent. In case of diarrhea, the intervals between feedings should not exceed 2.5 hours.
La bolnavii cu rectocolită ulceroasă nespecifică se dereglează îndeosebi metabolismul proteic din cauza micşorării asimilării proteinelor în intestin şi pierderii lor cu masele diareice. În asemenea situaţii, alimentarea trebuie să conţină o cantitate majorată de proteine (130,0…150,0 g pe zi). Pe larg se utilizează salazopreparatele (sulfosalazin, salazopirin, salazodimetoxin), preparatele acidului aminosalicilic (mesalazin şi analogii lui cu denumirea comercială salofalc, mezacol, pentază) şi hormonii corticosteroizi [1]. In patients with nonspecific ulcerative colitis, protein metabolism is particularly disturbed due to reduced protein assimilation in the intestine and their loss with diarrheal masses. In such situations, the diet should contain an increased amount of protein (130.0…150.0 g per day). Salazo preparations (sulfosalazine, salazopyrin, salazodimethoxin), aminosalicylic acid preparations (mesalazine and its analogues with the trade names salofalc, mesacol, pentaza) and corticosteroid hormones are widely used [1].
Însă utilizarea preparatelor menţionate este limitată din cauza acţiunii negative, şi anume provoacă anemie hemolitică, hepatică toxică, nefrită interstiţială şi duc la apariţia recidivelor frecvente. However, the use of the aforementioned preparations is limited due to their negative effects, namely, they cause hemolytic anemia, toxic liver disease, interstitial nephritis, and lead to frequent relapses.
Este cunoscută metoda de tratament al rectocolitei ulceroase nespecifice prin administrarea salazopiridazinei prin microclistere [2]. The method of treating nonspecific ulcerative colitis by administering salazopyridazine via micro-enemas is known [2].
Însă această metodă este apreciată cu rezultate bune numai în cazul localizării procesului patologic în intestinul rect. However, this method is appreciated with good results only in the case of localization of the pathological process in the rectum.
Este cunoscută, de asemenea, metoda de tratament al rectocolitei ulceroase nespecifice prin 2…3 autoreinfuzii de sânge iradiat cu raze ultaviolete cu interval de 3…5 zile, apoi peste 4…7 zile per os se indică sulfosalazin şi injectarea ulceraţiilor mucoasei colonului cu 30…90 ml de masă leucocitară zilnic de 4…8 ori [3]. The method of treating nonspecific ulcerative colitis is also known through 2…3 autoinfusions of blood irradiated with ultraviolet rays with an interval of 3…5 days, then after 4…7 days, oral sulfosalazine is indicated and the colon mucosal ulcerations are injected with 30…90 ml of leukocyte mass daily 4…8 times [3].
Însă folosirea îndelungată repetată a masei leucocitare duce la dezvoltarea reacţiilor alergice, micşorarea esenţială a sintezei imunoglobulinei A şi la dereglarea imunităţii. However, prolonged repeated use of leukocyte mass leads to the development of allergic reactions, a significant decrease in immunoglobulin A synthesis, and immune dysregulation.
Mai este cunoscută metoda de tratament al rectocolitei ulceroase cu sulfosalazin sau salofalc, sau mesalazin câte 2,0…4,0 ml pe zi, metragil intravenos câte 500 mg de 2 ori pe zi, nistatin câte 2 mln unităţi pe zi, pe parcursul a 10 zile, melaxen câte 3 mg cu 40 min înainte de somn pe parcursul a 30 zile [4]. Another known method of treating ulcerative colitis is sulfosalazine or salofalc, or mesalazine 2.0…4.0 ml per day, intravenous metragil 500 mg 2 times a day, nystatin 2 million units per day, for 10 days, melaxen 3 mg 40 min before bedtime for 30 days [4].
Însă şi această metodă de tratament nu provoacă remisii de lungă durată, deoarece sunt posibile recidive repetate cu complicaţii caracteristice. However, this treatment method also does not cause long-term remissions, as repeated relapses with characteristic complications are possible.
Este cunoscută metoda de tratament al rectocolitei ulceroase nespecifice prin folosirea suspensiei de hidrocortizon în microclistere [5]. The method of treating nonspecific ulcerative colitis by using hydrocortisone suspension in microclysters is known [5].
Folosirea steroizilor în tratamentul rectocolitei ulceroase nespecifice conform metodelor cunoscute, pe lângă efectul pozitiv, au şi acţiune negativă - duc la micşorarea imunităţii, la retenţia ionilor de natriu şi eliminarea ionilor de kaliu, ceea ce intensifică dereglările hidrosaline provocate de boala de bază, deprimă funcţia suprarenarelor, poate duce la dezvoltarea diabetului zaharat şi ulcerelor traiectului digestiv. The use of steroids in the treatment of nonspecific ulcerative colitis according to known methods, in addition to the positive effect, also has a negative effect - they lead to a decrease in immunity, to the retention of sodium ions and the elimination of potassium ions, which intensifies the hydrosaline disorders caused by the underlying disease, depresses the function of the adrenal glands, and can lead to the development of diabetes mellitus and ulcers of the digestive tract.
Cea mai frecventă complicaţie a terapiei cu steroizi la bolnavii cu rectocolită ulceroasă este regenerarea lentă a epiteliului mucoasei intestinale, în consecinţă procesul patologic recidivează la aceşti bolnavi. The most common complication of steroid therapy in patients with ulcerative colitis is the slow regeneration of the intestinal mucosal epithelium, as a result of which the pathological process recurs in these patients.
Este cunoscută, de asemenea, metoda de tratament al rectocolitei ulceroase nespecifice cu utilizarea salofalcului şi a analogilor lui în pastile, câte 0,5 mg de 4 ori pe zi, iar în cazul afectării porţiunii distale a intestinului (proctita, proctosigmoidita) sub formă de supozitorii şi clistire [6]. The method of treating nonspecific ulcerative colitis with the use of salofalk and its analogues in pills, 0.5 mg 4 times a day, and in the case of damage to the distal portion of the intestine (proctitis, proctosigmoiditis) in the form of suppositories and enemas is also known [6].
Dezavantajul acestei metode constă în frânarea proceselor regenerative ale ulceraţiilor mucoasei intestinului, micşorarea rezistenţei la infecţie şi acţiunea toxică asupra ficatului şi rinichilor. The disadvantage of this method is the inhibition of the regenerative processes of ulcerations of the intestinal mucosa, the decrease in resistance to infection and the toxic action on the liver and kidneys.
Cea mai apropiată soluţie este metoda de tratament al bolilor inflamatoare a intestinului, care constă în utilizarea preparatelor cu conţinut de acid 5-aminosalicilic - sulfosalazin, salofalc sau mesalazin câte 2,0…4,0 ml pe zi, metragil 500 mg de 2 ori pe zi pe parcursul a 10 zile cu trecerea la metronidazol (trihopol) câte 25 mg de 4 ori pe zi per os, nistatin 500 mii unităţi de 4 ori pe zi [7]. The closest solution is the method of treating inflammatory bowel diseases, which consists of using preparations containing 5-aminosalicylic acid - sulfosalazine, salofalk or mesalazine 2.0…4.0 ml per day, metragil 500 mg 2 times a day for 10 days with the transition to metronidazole (trichopol) 25 mg 4 times a day per os, nystatin 500 thousand units 4 times a day [7].
Însă dezavantajul metodei este micşorarea lentă a manifestărilor clinice: diareea, eliminările sangvine la defecaţie. However, the disadvantage of the method is the slow reduction of clinical manifestations: diarrhea, bloody stools.
Problema pe care o rezolvă invenţia propusă constă în elaborarea unei metode de tratament al rectocolitei ulceroase nespecifice eficiente la toate formele de debut al maladiei, cu obţinerea remisiei clinice a maladiei, precum şi restabilirea structurii mucoasei colonului, micşorarea riscului de recidivare a bolii. The problem solved by the proposed invention consists in developing a method for treating non-specific ulcerative colitis that is effective in all forms of disease onset, achieving clinical remission of the disease, as well as restoring the structure of the colon mucosa, reducing the risk of disease recurrence.
Conform invenţiei, metoda revendicată constă în aceea că se administrează acid 5-aminosalicilic în capsule câte 1200…4000 mg pe zi, per os, timp de o lună, soluţie de 2-(2-metil-5-nitro1H-imidazol-1-il)etanol câte 500 mg, intravenos, de 2 ori pe zi, soluţie de acid 1-ciclopropil-6-fluoro-4-oxo-7-(piperazin-1-il)-quinoline-3-carboxilic câte 1,0 ml, intravenos de 2 ori pe zi şi soluţie de 5-(aminosulfonil)N-[(1-etilpirolidin-2-il)metil]-2-metoxibenzamidă câte 2,0 ml seara, timp de 7 zile, se efectuează terapia de dezintoxicare, transfuzii de masă eritrocitară, plasmă, albumină, totodată se administrează acid 5-aminosalicilic în microclistire peste o zi, timp de o lună. În cazul afectării regiunii rectosigmoidale, acidul 5-aminosalicilic se administrează sub formă de gel, câte 500 mg, o dată pe zi, iar în cazul afectării colonului, acidul 5-aminosalicilic se administrează sub formă de spumă câte 2 g, de 2 ori pe zi. According to the invention, the claimed method consists in administering 5-aminosalicylic acid in capsules at 1200…4000 mg per day, orally, for one month, 2-(2-methyl-5-nitro1H-imidazol-1-yl)ethanol solution at 500 mg, intravenously, 2 times a day, 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-quinoline-3-carboxylic acid solution at 1.0 ml, intravenously 2 times a day and 5-(aminosulfonyl)N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide solution at 2.0 ml in the evening, for 7 days, detoxification therapy is performed, transfusions of red blood cell mass, plasma, albumin, at the same time 5-aminosalicylic acid is administered in micro-enemas every other day, for one month. In case of damage to the rectosigmoid region, 5-aminosalicylic acid is administered in the form of a gel, 500 mg, once a day, and in case of damage to the colon, 5-aminosalicylic acid is administered in the form of a foam, 2 g, 2 times a day.
Rezultatul invenţiei constă în obţinerea unei remisii clinice de lungă durată la toate formele de debut al maladiei, restabilirea structurii mucoasei colonului şi micşorarea numărului de recidive ale maladiei. The result of the invention consists in obtaining a long-term clinical remission in all forms of onset of the disease, restoring the structure of the colon mucosa and reducing the number of relapses of the disease.
Avantajul metodei propuse constă în faptul că preparatul mesalazin se introduce sub formă de gel (pentacol) sau spumă (asacol) pe mucoasa afectată a colonului şi pozitiv acţionează asupra indicelui fagocitar al leucocitelor. The advantage of the proposed method is that the mesalazine preparation is introduced in the form of a gel (pentacol) or foam (asacol) on the affected colon mucosa and has a positive effect on the phagocytic index of leukocytes.
Metoda se efectuează în felul următor. Pacientul se internează în staţionar, unde i se efectuează toate manipulaţiile clinice şi paraclinice pentru confirmarea diagnosticului, după care se administrează acid 5-aminosalicilic în capsule câte 1200…4000 mg pe zi, per os, timp de o lună, soluţie de 2-(2-metil-5-nitro1H-imidazol-1-il)etanol câte 500 mg, intravenos, de 2 ori pe zi, soluţie de acid 1-ciclopropil-6-fluoro-4-oxo-7-(piperazin-1-il)-quinoline-3-carboxilic câte 1,0 ml, intravenos de 2 ori pe zi şi soluţie de 5-(aminosulfonil)N-[(1-etilpirolidin-2-il)metil]-2-metoxibenzamidă câte 2,0 ml seara, timp de 7 zile, se efectuează terapia de dezintoxicare, transfuzii de masă eritrocitară, plasmă, albumină, totodată se administrează acid 5-aminosalicilic în microclistire peste o zi, timp de o lună. În cazul afectării regiunii rectosigmoidale, acidul 5-aminosalicilic se administrează sub formă de gel, câte 500 mg, o dată pe zi, iar în cazul afectării colonului, acidul 5-aminosalicilic se administrează sub formă de spumă câte 2 g, de 2 ori pe zi. The method is performed as follows. The patient is admitted to the hospital, where all clinical and paraclinical manipulations are performed to confirm the diagnosis, after which 5-aminosalicylic acid is administered in capsules at 1200…4000 mg per day, orally, for one month, 2-(2-methyl-5-nitro1H-imidazol-1-yl)ethanol solution at 500 mg, intravenously, 2 times a day, 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-quinoline-3-carboxylic acid solution at 1.0 ml, intravenously 2 times a day and 5-(aminosulfonyl)N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide solution at 2.0 ml in the evening, for 7 days, detoxification therapy is performed, transfusions of red blood cell mass, plasma, albumin, and at the same time, salicylic acid is administered. 5-aminosalicylic acid in micro-enema every other day for a month. In case of damage to the rectosigmoid region, 5-aminosalicylic acid is administered in the form of a gel, 500 mg, once a day, and in case of damage to the colon, 5-aminosalicylic acid is administered in the form of a foam, 2 g, 2 times a day.
Exemplul 1 Example 1
Pacienta G., 34 ani. A fost internată cu diagnosticul de rectocolită ulceroasă nespecifică, evoluţie de gravitate medie în fază de acutizare. Esofagită. Gastroduodenită erozivă. La internare starea de gravitate medie cu acuze la scaun frecvent, diareic până la 10…12 ori pe zi cu eliminări de mucozitate, puroi, sânge proaspăt, dureri abdominale, balonarea abdomenului, febrilitate. Patient G., 34 years old. She was admitted with the diagnosis of nonspecific ulcerative colitis, evolution of moderate severity in the exacerbation phase. Esophagitis. Erosive gastroduodenitis. On admission, the condition was of moderate severity with complaints of frequent stools, diarrhea up to 10…12 times a day with mucus, pus, fresh blood, abdominal pain, abdominal bloating, fever.
S-a investigat: analiza generală şi biochimica a sângelui, analiza generală a urinei. USG organelor abdominale şi a rinichilor, FEGDS, FCS. S-a indicat tratament: mesalazin în doză de 2400 mg/zi 2 săptămâni, sol. metragil 500 mg de 2 ori/zi i/v - 7 zile, sol. eglonil 2 ml seara timp de 7 zile, sol. ciprofloxacină câte 1,0 intravenos de 2 ori pe zi, timp de 7 zile, hemotransfuzii cu masă eritrocitară 200 ml şi plasmă proaspătă 200 ml, timp de 2 zile, terapie infuzională cu spasmolitice, analgetice, hemostatice, vitaminoterapie, clistire cu spumă (asacol) 2 g peste o zi. S-a tratat în staţionar 15 zile, starea cu ameliorare, s-a externat în stare satisfăcătoare. Tratament ambulatoriu îndelungat la medicul de familie. Peste 2 săptămâni de tratament doza de mesalazină s-a micşorat la 1600 mg/zi, timp de 2 săptămâni. În primele 2 săptămâni de tratament frecventa scaunului s-a micşorat până la 2, 3, 4 ori/zi, fără amestec patologic, dispariţia durerilor în abdomen şi a febrei. FCS repetată a fost efectuată la 3…4 luni după externare din staţionar. În mucoasa colonului s-a observat restabilirea completă a structurii mucoasei şi dispariţia semnelor de inflamaţie. Investigations included: general and biochemical blood analysis, general urine analysis. USG of abdominal organs and kidneys, FEGDS, FCS. Treatment was indicated: mesalazine in a dose of 2400 mg/day for 2 weeks, metragil sol. 500 mg 2 times/day i/v - 7 days, eglonil sol. 2 ml in the evening for 7 days, ciprofloxacin sol. 1.0 intravenously 2 times a day for 7 days, hemotransfusions with erythrocyte mass 200 ml and fresh plasma 200 ml for 2 days, infusion therapy with spasmolytics, analgesics, hemostatics, vitamin therapy, foam enema (asacol) 2 g every other day. He was treated inpatient for 15 days, the condition improved, he was discharged in satisfactory condition. Long-term outpatient treatment at the family doctor. After 2 weeks of treatment, the dose of mesalazine was reduced to 1600 mg/day for 2 weeks. In the first 2 weeks of treatment, the stool frequency decreased to 2, 3, 4 times/day, without pathological admixture, the disappearance of abdominal pain and fever. Repeated FCS was performed 3…4 months after discharge from the hospital. In the colon mucosa, complete restoration of the mucosal structure and the disappearance of signs of inflammation were observed.
Exemplul 2 Example 2
Pacienta C. 26 ani. A fost internată cu diagnosticul de rectocolită ulceroasă nespecifică. Diverticuloză cu diverticulită erozivă. Evoluţie severă. Hemoragie intestinală. Anemie posthemoragică gr. 3-4. Patient C. 26 years old. She was admitted with the diagnosis of nonspecific ulcerative colitis. Diverticulosis with erosive diverticulitis. Severe evolution. Intestinal hemorrhage. Posthemorrhagic anemia gr. 3-4.
A fost internată în staţionar în stare gravă cu acuze la slăbiciune generală, cefalee, febră 38,0…39,0°C, scaun diareic 5…6 ori/zi cu sânge proaspăt în cantităţi mari 80…100 ml, dureri violente în abdomen, pierdere în pondere 10…12 kg, inapetenţă, diureză în cantităţi insuficiente de 2…3 ori/zi. She was hospitalized in serious condition with complaints of general weakness, headache, fever 38.0…39.0°C, diarrheal stools 5…6 times/day with fresh blood in large quantities 80…100 ml, violent abdominal pain, weight loss 10…12 kg, loss of appetite, insufficient diuresis 2…3 times/day.
S-a investigat: analiza generală şi biochimică a sângelui, analiza generală a urinei. USG organelor abdomenului şi a rinichilor, FEGDS, FCS. S-a indicat tratament: mesalazin în doză de 4000 mg/zi, 2 săptămâni, sol. metragil 500 mg de 2 ori/zi i/v - 7 zile, terapie infuzională cu spasmolitice, analgetice, hemostatice, vitaminoterapie, preparatele vitaminei K, transfuzii de masă eritrocitară AB(IV0) Rh+(pozitiv) 800 ml cu interval de 5 zile, plasmă sângvină proaspăt congelată 800 ml cu interval de 4 zile, albumină 400 ml cu interval de 4 zile, clistire cu spumă (asacol) 4 g/zi, pentacol câte 500 mg, peste o zi, sol. eglonil 2 ml seara, 7 zile. S-a tratat staţionar 30 zile, starea cu ameliorare, s-a externat în stare satisfăcătoare. Tratament ambulatoriu îndelungat la medicul de familie. Peste 2 săptămâni de tratament doza de mesalazin s-a micşorat la 3200 mg/zi, timp de o săptămână, după care doza de mesalazin s-a redus la 2400 mg/zi, timp de o săptămână. În primele 2 săptămâni de tratament frecvenţa scaunului s-a micşorat până la 2, 3, 4 ori/zi, fără amestec patologic, dispariţia durerilor în abdomen şi a febrei. La externare din staţionar frecvenţa scaunului a fost de 2 ori/zi semiformat. FCS repetată a fost efectuată la 3…4 luni după externarea din staţionar. În mucoasa colonului s-a observat restabilirea completă a structurii mucoasei şi dispariţia semnelor de inflamaţie. Investigations included: general and biochemical blood analysis, general urine analysis. USG of the abdominal organs and kidneys, FEGDS, FCS. Treatment was indicated: mesalazine in a dose of 4000 mg/day, 2 weeks, metragil sol. 500 mg 2 times/day i/v - 7 days, infusion therapy with spasmolytics, analgesics, hemostatics, vitamin therapy, vitamin K preparations, transfusions of AB(IV0) Rh+(positive) erythrocyte mass 800 ml with an interval of 5 days, fresh frozen blood plasma 800 ml with an interval of 4 days, albumin 400 ml with an interval of 4 days, foam enema (asacol) 4 g/day, pentacol 500 mg each, every other day, eglonil sol. 2 ml in the evening, 7 days. He was treated as an inpatient for 30 days, his condition improved, he was discharged in a satisfactory condition. Long-term outpatient treatment at the family doctor. After 2 weeks of treatment, the dose of mesalazine was reduced to 3200 mg/day for one week, after which the dose of mesalazine was reduced to 2400 mg/day for one week. In the first 2 weeks of treatment, the stool frequency decreased to 2, 3, 4 times/day, without pathological admixture, the abdominal pain and fever disappeared. Upon discharge from the inpatient, the stool frequency was 2 times/day semi-formed. Repeated FCS was performed 3…4 months after discharge from the inpatient. In the colon mucosa, complete restoration of the mucosal structure and the disappearance of signs of inflammation were observed.
1. Райхлин Н.Т. Синдром раздраженной кишки. Клинико-морфологические аспекты при лечении мелаксеном. Русский медицинский журнал, 2006, том 82, стр.1-6 1. Raikhlin N.T. Irritable bowel syndrome. Clinical and morphological aspects of treatment with melaxene. Русский медицинский журнал, 2006, volume 82, str.1-6
2. Валинкевич Л.Н. Способ лечения неспецифического язвенного колита. Гастроентерология в гериатрии. Ленинград, 1987, стр. 194-195 2. Valinkevich L.N. Method of treatment of non-specific ulcerative colitis. Gastroenterology in geriatrics. Leningrad, 1987, p. 194-195
3. RU 2056849 C1 1996.03.27 3. RU 2056849 C1 1996.03.27
4. RU 2009117955 A 2010.07.20 4. RU 2009117955 A 2010.07.20
5. Левитан М.Х. Применение кортикостероидов ректально при неспецифическом язвенном колите. Тезисы докл. 11. Всесоюзой конф. Проктологов, Москва, 1981, стр.96-98 5. Levitan М.Х. Rectal application of corticosteroids in non-specific ulcerative colitis. Thesis dokl. 11. All-Union Conf. Проктологов, Moscow, 1981, стр.96-98
6. Григорьева К. Современное состояние проблемы неспецифического язвенного колита и болезни Крона. Врач, 1993 № 3, стр.7-10 6. Григорьева К. Current state of non-specific ulcerative colitis and Crohn's disease. Doctor, 1993 № 3, стр.7-10
7. Адлер Г. Болезнь Крона и язвенный колит. Москва, 2011, стр. 285 7. Adler Г. Crohn's disease and ulcerative colitis. Moscow, 2011, p. 285
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20110128A MD480Z (en) | 2011-07-07 | 2011-07-07 | Method for treating acute ulcerative nonspecific colitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20110128A MD480Z (en) | 2011-07-07 | 2011-07-07 | Method for treating acute ulcerative nonspecific colitis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD480Y MD480Y (en) | 2012-02-29 |
| MD480Z5 MD480Z5 (en) | 2012-09-30 |
| MD480Z true MD480Z (en) | 2012-09-30 |
Family
ID=45815378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20110128A MD480Z (en) | 2011-07-07 | 2011-07-07 | Method for treating acute ulcerative nonspecific colitis |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD480Z (en) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8903914D0 (en) * | 1989-11-22 | 1989-11-22 | Draco Ab | ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES |
| RU2056849C1 (en) * | 1992-03-03 | 1996-03-27 | Кириллов Владимир Анатольевич | Method for treating the cases of nonspecific ulcerous colitis |
| CN1142765A (en) * | 1993-12-01 | 1997-02-12 | 三共株式会社 | inflammatory cytokine production inhibitor containing polyprenyl derivative as active ingredient |
| PT1074268E (en) * | 1998-03-17 | 2008-02-28 | Chugai Pharmaceutical Co Ltd | Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodies |
| RU2200007C2 (en) * | 1999-03-05 | 2003-03-10 | Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра СО РАМН | Method for treating patients for nonspecific ulcerating colitis |
| JP4210454B2 (en) * | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | Inflammatory bowel disease treatment |
| RU2165758C1 (en) * | 2000-09-04 | 2001-04-27 | Андрей Эдуардович Дорофеев | Method for treating ulcerative colitis |
| RU2318537C2 (en) * | 2001-04-06 | 2008-03-10 | Юниверсити Оф Бристоль | Application of cd25-binding molecules for treatment of steroid-resistant patients |
| KR100824491B1 (en) * | 2001-10-05 | 2008-04-22 | 콤비네이토릭스, 인코포레이티드 | Combination for the treatment of immunoinflammatory diseases |
| RU2215546C1 (en) * | 2002-03-29 | 2003-11-10 | Алтайский государственный медицинский университет | Method for treating inspecific ulcerous colitis |
| ATE477268T1 (en) * | 2003-01-28 | 2010-08-15 | Ironwood Pharmaceuticals Inc | COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS |
| BRPI0507384A (en) * | 2004-02-03 | 2007-07-10 | Nippon Shinyaku Co Ltd | glycosidically 5-aminosalicylic acid prodrug |
| PL1776336T3 (en) * | 2004-03-23 | 2010-06-30 | Dompe Farm Spa | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them |
| PL1747008T3 (en) * | 2004-04-28 | 2015-10-30 | Nutrition Science Partners Ltd | Crude extracts from andrographis paniculata |
| RU2328298C1 (en) * | 2007-03-30 | 2008-07-10 | Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) | Method of non-specific ulcerative colitis treatment |
| RU2394571C1 (en) * | 2009-05-14 | 2010-07-20 | Государственное бюджетное учреждение здравоохранения города Москвы "Городская клиническая больница № 24" Департамента здравоохранения города Москвы | Method of treating inflammatory intestinal diseases |
| RU2419443C1 (en) * | 2009-12-08 | 2011-05-27 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Method of treating patients with ulcerative colitis |
| RU2460554C1 (en) * | 2011-01-12 | 2012-09-10 | Петр Леонидович Щербаков | Method of ulcerative colitis and crohn's disease therapy |
-
2011
- 2011-07-07 MD MDS20110128A patent/MD480Z/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD480Z5 (en) | 2012-09-30 |
| MD480Y (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3915566B1 (en) | Composition for preventing or treating inflammatory bowel disease, containing, as active ingredient, taurodeoxycholic acid or pharmaceutically acceptable salt thereof | |
| Lan et al. | L-arginine ameliorates lipopolysaccharide-induced intestinal inflammation through inhibiting the TLR4/NF-κB and MAPK pathways and stimulating β-defensin expression in vivo and in vitro | |
| Stolman et al. | Pyoderma gangrenosum and rheumatoid arthritis | |
| US9913867B2 (en) | Composition comprising extract of mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis | |
| US20120157417A1 (en) | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | |
| US10183040B2 (en) | Method for regulation of lipid metabolism | |
| Hawrysz et al. | Zinc: an undervalued microelement in research and treatment | |
| WO2010127557A1 (en) | Use of lanostanes and extracts from poria cocos for treating cachexia | |
| Chebion et al. | Drug-induced nephrolithiasis and crystalluria: the particular case of the sulfasalazine derivatives | |
| CN113304133B (en) | Application of kaurane compounds in preparation of medicines for preventing and treating inflammatory bowel diseases | |
| CN111228281A (en) | New application of diammonium glycyrrhizinate | |
| CA3200117A1 (en) | Composition for preventing, improving or treating inflammatory bowel disease, comprising isatidis folium extract | |
| MD480Z (en) | Method for treating acute ulcerative nonspecific colitis | |
| CN106361740A (en) | Liver protection effect and application of sulforaphen in non-alcoholic fatty liver | |
| CN116531410A (en) | Application of staphylococcus albus in preparation of composition | |
| Uttamani et al. | Therapeutic Modalities in the management of COVID-19: A worldwide landscape | |
| TWI432203B (en) | Use of lanostane and poria extract in treating cachexia | |
| CN115444923A (en) | Application of oyster peptide in preparation of medicine for treating and/or preventing acute lung injury | |
| CN120093735B (en) | Obesity suppressing composition, inhibitor and application thereof | |
| CN116098886B (en) | Pharmaceutical composition and application thereof | |
| CN116549428B (en) | New application of 4-hydroxyisoleucine | |
| CN117815261B (en) | New medical application of saw palmetto fruit extract and soft capsule thereof | |
| CN120771134A (en) | Application of oat characteristic functional component in preparation of product for improving intestinal health | |
| US20070275109A1 (en) | Eggplant extract for medical treatments | |
| CN117224554A (en) | Application of Capelliposide A in preparation of medicines for treating ulcerative colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4Y | Validity of short term patent extended [from 6 to 10 years] |
Expiry date: 20210707 |
|
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |